Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat i starsze, które rozumieją badanie i mogą wziąć w nim udział.
- •Pacjenci z potwierdzonym rakiem pęcherza moczowego o niskim stopniu złośliwości, który nie nacieka mięśni, zdiagnozowanym w ciągu ostatnich 6 tygodni.
- •Wykryta specyficzna mutacja lub połączenie genów FGFR3.
- •Zidentyfikowano widoczne zmiany nowotworowe w pęcherzu moczowym.
- •Brak oznak raka dróg moczowych wyższych lub cewki moczowej prostaty w ciągu ostatnich 6 miesięcy.
- •Nie przyjmowano wcześniej leczenia BCG w ciągu ostatniego roku.
- •Nie podawano chemioterapii do pęcherza w ciągu ostatnich 8 tygodni.
✗ Disqualifies
- •Pacjenci z zaawansowanym rakiem pęcherza.
- •Pacjenci, u których występują inne poważne choroby.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (46)
Urology Centers of Alabama
Homewood, United States
Arkansas Urology
Little Rock, United States
Tri Valley Urology - Murrieta
Murrieta, United States
Eisenhower Medical Associates
Rancho Mirage, United States
Om Research LLC
San Diego, United States
Associated Urological Specialists
Chicago Ridge, United States
Duly Health and Care
Lisle, United States
Urology of Indiana
Greenwood, United States
First Urology
Jeffersonville, United States
University of Kansas Medical Center (KUMC)
Kansas City, United States
Johns Hopkins University
Baltimore, United States
Greater Boston Urology
Plymouth, United States
Specialty Clinical Research of St. Louis
St Louis, United States
Atlantic Health System
Morristown, United States
New Jersey Urology, LLC (Summit Health - Washington Township)
Voorhees Township, United States
NYU Langone Health
New York, United States
Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers
New York, United States
Associated Medical Professionals of NY
Syracuse, United States
The Bronx Veterans Medical Research Foundation, Inc.
The Bronx, United States
Duke Cancer Institute
Durham, United States
Associate Urologist of North Carolina
Raleigh, United States
The James at Brain and Spine Hospital (OSU)
Columbus, United States
Oregon Urology Institute
Springfield, United States
MidLantic Urology
Bala-Cynwyd, United States
Keystone Urology Specialists
Lancaster, United States
Medical University of South Carolina
Charleston, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Lowcounty Urology Clinics, P.A.
North Charleston, United States
Conrad Pearson-Memphis
Germantown, United States
Urology Associates PC
Nashville, United States
Urology Austin
Austin, United States
Urology Clinics of North Texas
Dallas, United States
Baylor College of Medicine
Houston, United States
Urology San Antonio
San Antonio, United States
Epworth Freemasons-Victoria Parade
Richmond, Australia
Istituti Fisioterapici Ospitalieri (IFO)
Rome, Italy
Istituto Europeo di Oncologia
Milan, Italy
Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara
Pisa, Italy
ASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie
Pozzuoli, Italy
Hospital del Mar
Barcelona, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Universitario 12 de Oc
Madrid, Spain
Hospital Quirón Barcelona
Barcelona, Spain
MD Anderson Cancer Center - Madrid
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Trial contact
Grace Indyk
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.